A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

This study is testing aumolertinib — a targeted therapy for a specific type of lung cancer — in European patients with advanced non-small cell lung cancer (NSCLC) that carries an EGFR mutation. **You may be eligible if...** - You are 18 or older and of European descent living in Europe - You have been diagnosed with advanced or metastatic NSCLC - Your tumor has an EGFR mutation (specifically exon 19 deletion or L858R) - Either you have not yet received treatment for your advanced cancer, OR you have previously received treatment and your cancer progressed on a prior EGFR-targeting drug **You may NOT be eligible if...** - Your lung cancer has small cell elements - You have had unresolved serious side effects from prior treatment - You have had another primary cancer in the past 5 years (with some exceptions) - You have active brain metastases that are not stable - You have a history of serious lung inflammation (ILD/pneumonitis) Talk to your doctor to see if this trial is right for you.